Yüklüyor......
The CXCR4 antagonist plerixafor is a potential therapy for myelokathexis, WHIM syndrome
Mutations in CXCR4 cause severe leukopenia in myelokathexis or WHIM syndrome. Plerixafor inhibits binding of CXCR4 to its ligand CXCL12. We investigated the effects of plerixafor (0.04 to 0.24 mg/kg) administered at 2-4 day intervals in 6 patients. Outcome measures were the patients' complete b...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2011
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3673761/ https://ncbi.nlm.nih.gov/pubmed/21835955 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-06-360586 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|